3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Terminated
4
Unknown
3
Recruiting
2
Withdrawn
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
10
Gastrointestinal
3
Thoracic
1
CNS
1
Conditions
Colorectal Neoplasms
2
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Oxaliplatin
288
Capecitabine
218
Fluorouracil
213
Irinotecan
146
Leucovorin
140
Gemcitabine
124
S 1 (combination)
110
apatinib
109
Cisplatin
102
Bevacizumab
99
Drug Therapy
98
Radiotherapy
97
Paclitaxel
97
camrelizumab
89
sintilimab
79
Cetuximab
75
lenvatinib
62
Neoadjuvant Therapy
61
tislelizumab
55
Surgical Procedures, Operative
54
Sorafenib
53
Folfox protocol
53
toripalimab
52
Docetaxel
52
130-nm albumin-bound paclitaxel
47
Laparoscopy
41
HMPL-013
40
XELOX
39
Radiosurgery
36
Albumin-Bound Paclitaxel
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
Ado-Trastuzumab Emtansine
×
Gastrointestinal
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT03418558
2018-10-31
RESCUE
Fondazione del Piemonte per l'Oncologia
Phase 2
Unknown
13 enrolled
NCT03225937
2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2
Unknown
54 enrolled